Results 1 to 10 of about 13,230 (236)

Propafenone facilitates mitochondrial-associated ferroptosis and synergizes with immunotherapy in melanoma [PDF]

Journal for ImmunoTherapy of Cancer
Background Despite the successful application of immunotherapy, both innate and acquired resistance are typical in melanoma. Ferroptosis induction appears to be a potential strategy to enhance the effectiveness of immunotherapy. However, the relationship
Hong Liu, Qian Zhou, Yi He, Xiang Chen, Hui Su, Yu Meng, Yating Dian, Lei Yao, Yuming Sun, Daishi Li, Yixiao Xiong, Furong Zeng, Xiaowei Liang, Guangtong Deng   +13 more
doaj   +3 more sources

A case of lethal suicidal intoxication with propafenone and diazepam [PDF]

Annals of Noninvasive Electrocardiology
Diazepam poisoning is a common emergency situation, but propafenone poisoning is relatively rare. We reported a case of propafenone poisoning combined with diazepam.
Shuangbing Yan, Ting Xin, Xiaojie Luo, Yu Wang, Bingwei Chen   +4 more
doaj   +3 more sources

Influence of CYP2D6 genetic variation on adverse events with propafenone in the pediatric and young adult population

Clinical and Translational Science, 2022
Propafenone is an antiarrhythmic drug metabolized primarily by cytochrome P450 2D6 (CYP2D6). In adults, propafenone adverse events (AEs) are associated with CYP2D6 poor metabolizer status; however, pediatric data are lacking.
Sudeep D. Sunthankar, Prince J. Kannankeril, Andrea Gaedigk, Andrew E. Radbill, Frank A. Fish, Sara L. Van Driest   +5 more
doaj   +2 more sources

The Efficacy Comparison Between Guan-Fu Base A Hydrochloric Injection vs. Propafenone Hydrochloric Injection in the Treatment of Arrhythmia: Systemic Review and Meta-Analysis

Frontiers in Cardiovascular Medicine, 2021
Objective: To determine using a systematic assessment and meta-analysis if GFA injection is an appropriate substitute of propafenone for arrhythmic.Design: Conduct a systematic review and meta-analysis of randomized controlled trials.Data Source: PubMed,
Jinming Song, Yao Tang, Chao Gao, Xiaofeng Hou, Xinyue Liu, Zongpei Xu   +5 more
doaj   +2 more sources

Chronic Propafenone Application Increases Functional K_IR2.1 Expression In Vitro

Pharmaceuticals, 2023
Expression and activity of inwardly rectifying potassium (KIR) channels within the heart are strictly regulated. KIR channels have an important role in shaping cardiac action potentials, having a limited conductance at depolarized potentials but ...
Encan Li, Willy Kool, Liset Woolschot, Marcel A. G. van der Heyden   +3 more
doaj   +2 more sources

Propafenone-Induced QRS Widening in a Child With Arrhythmogenic Right Ventricular Cardiomyopathy: A Case Report and Literatures Review

Frontiers in Pediatrics, 2020
Arrhythmogenic right ventricular cardiomyopathy (ARVC) is a rare cardiac disease in children, and can lead to sudden cardiac death (SCD). Propafenone is classIC antiarrhythmic medication, and its side effects include cardiovascular compromise in the form
Yan-qiu Chu, Ce Wang, Xue-mei Li, Hong Wang   +3 more
doaj   +2 more sources

Propafenone-induced liver injury in an elderly patient with paroxysmal atrial fibrillation--a new case report and literature review [PDF]

Acta Poloniae Pharmaceutica, 2023
Antiarrhythmic drugs are used more and more often, which is related to the aging of the population and the growing number of arrhythmias, especially atrial fibrillation (AF).
Katarzyna Giedzicz, Marcin Dytkowski, Justyna Rentflejsz, Marta Swietek, Aleksandra Wojszel, Zyta Beata Wojszel   +5 more
doaj   +2 more sources

Medical therapy with flecainide and propafenone in atrial fibrillation: Long-term clinical experience in the tertiary care setting

Cardiology Journal, 2023
BACKGROUND: Flecainide and propafenone are Class Ic antiarrhythmic drugs that block the cardiac fast inwards Na+ current and are used for rhythm control in patients with atrial fibrillation (AF). However, data on long-term clinical efficacy and safety of
Boldizsar Kovacs, Haci Yakup Yakupoglu, Urs Eriksson, Nazmi Krasniqi, Firat Duru   +4 more
doaj   +2 more sources

The Effect of CYP2D6 Phenotypes on the Pharmacokinetics of Propafenone: A Systematic Review and Meta-Analysis

Pharmaceutics, 2022
Propafenone (PPF) is a class 1C antiarrhythmic agent mainly metabolized by cytochrome (CYP) 2D6, CYP1A2, and CYP3A4. Previous studies have shown that CYP2D6 polymorphism influences the pharmacokinetics (PK) of PPF.
Quyen Thi Tran, In-hwan Baek, Na-young Han, Hwi-yeol Yun, Jung-woo Chae   +4 more
doaj   +2 more sources

Propafenone and propranolol dual toxicity

Journal of the American College of Emergency Physicians Open, 2020
Propranolol is a highly lipid‐soluble beta‐receptor antagonist and propafenone is a potent class 1c anti‐arrhythmic agent with strong Na‐channel blockade effect.
Moonis Farooq, Faisal Qureshi, Wael Kamkoum, Feras Abuzeyad   +3 more
doaj   +2 more sources